ASIAMEDIC LIMITED

ASIAMEDIC LIMITED

(Incorporated in the Republic of Singapore)
(Registration No. 197401556E)

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

TABLE OF CONTENTS

A CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	Note	Group 6 months ended 30.06.2026 ("1H2026") (Unaudited)	6 months ended 30.06.2025 ("1H2025") (Unaudited)	Increase/(Decrease)	
		$	$	$	%
Revenue	N4	**16,231,953**	**16,615,469**	**(383,516)**	**-2%**
Other income		269,175	355,052	(85,877)	-24%
Items of expense					
Consumables used		(985,660)	(1,025,812)	(40,152)	-4%
Personnel expenses		(7,459,434)	(8,025,753)	(566,319)	-7%
Depreciation of non-current assets					
- Plant and equipment		(426,030)	(466,260)	(40,230)	-9%
- Right-of-use assets		(1,138,473)	(1,503,828)	(365,355)	-24%
Maintenance of equipment		(319,274)	(245,230)	74,044	30%
Laboratory and consultancy fees		(3,567,761)	(3,343,655)	224,106	7%
Facility and admin fees		(739,808)	(715,022)	24,786	3%
Finance costs		(399,483)	(451,727)	(52,244)	-12%
Other operating expenses		(1,719,729)	(1,980,430)	(260,701)	-13%
Share of results of associates		214,343	170,634	43,709	26%
Loss before tax	N5	**(40,181)**	**(616,562)**	**(576,381)**	**-93%**
Income tax expense	N6	-	-		
Loss for the period		**(40,181)**	**(616,562)**	**(576,381)**	**-93%**
Attributable to:					
Owners of the Company		(71,221)	(38,603)	**32,618**	**84%**
Non-controlling interest		31,040	(577,959)	**608,999**	**NM**
		(40,181)	**(616,562)**	**(576,381)**	**-93%**
Loss per share for profit for the period attributable to the owners of the Company					
Basic (SGD in cent)	N7	(0.006)	(0.003)		
Diluted (SGD in cent)	N7	(0.006)	(0.003)		

Note: "NM" means not meaningful.

B CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

		Group		Company	
		30.06.2026 (Unaudited)	31.12.2025 (Audited)	30.06.2026 (Unaudited)	31.12.2025 (Audited)
	Note	$	$	$	$
Non-current assets					
Plant and equipment		3,766,310	4,168,083	18,883	25,185
Investment in subsidiaries		-	-	8,409,804	8,409,804
Investment in associates	N1	2,664,221	2,449,878	181,500	181,500
Right-of-use assets	N8.2	17,569,112	18,707,585	3,263,571	3,745,671
Deferred tax assets		891,000	891,000	-	-
		24,890,643	**26,216,546**	**11,873,758**	**12,362,160**
Current assets					
Inventories		87,439	142,425	-	-
Trade receivables		4,649,030	4,802,838	-	-
Other receivables and deposits		3,273,443	1,784,002	2,937,915	4,665,726
Prepayments		577,322	260,138	169,903	48,229
Other financial assets		4,995,662	3,991,907	4,995,662	3,991,907
Cash pledged as security		-	295,920	-	-
Cash and cash equivalents		3,455,206	5,694,448	290,954	741,004
		17,038,102	**16,971,678**	**8,394,434**	**9,446,866**
Current liabilities					
Trade payables		1,895,838	1,370,607	-	-
Other payables and accruals		2,882,887	3,448,112	1,917,940	3,038,164
Contract liabilities		650,496	800,864	-	-
Borrowings	N9	2,133,291	2,450,477	761,681	989,983
		7,562,512	**8,070,060**	**2,679,621**	**4,028,147**
Net current assets		**9,475,590**	**8,901,618**	**5,714,813**	**5,418,719**
Non-current liabilities					
Provision for reinstatement		1,601,505	1,592,064	475,899	471,201
Borrowings	N9	14,472,199	15,415,737	3,068,024	3,376,470
Deferred tax liabilities		16,065	16,065	-	-
		16,089,769	**17,023,866**	**3,543,923**	**3,847,671**
Net assets		**18,276,464**	**18,094,298**	**14,044,648**	**13,933,208**
Equity attributable to owners of the Company					
Share capital	N10	33,631,300	33,394,437	33,631,300	33,394,437
Treasury shares	N11	-	(2,866)	-	(2,866)
Other reserves		22,016	137,210	30,205	145,399
Accumulated losses		(17,449,094)	(17,475,685)	(19,616,857)	(19,603,762)
		16,204,222	16,053,096	14,044,648	13,933,208
Non-controlling interest		2,072,242	2,041,202	-	-
Total equity		**18,276,464**	**18,094,298**	**14,044,648**	**13,933,208**

C CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

Group	← Attributable to equity holders of the Company →						
	Share capital	Other reserves	Treasury shares	Accumulated losses	Total	Non-controlling interests	Total equity
	$	$	$	$	$	$	$
Balance at 1 January 2026	33,394,437	137,210	(2,866)	(17,475,685)	**16,053,096**	2,041,202	**18,094,298**
Loss for the period, representing total comprehensive income for the period	–	–	–	(71,221)	**(71,221)**	31,040	**(40,181)**
Exercise of share options and reissue of treasury shares	236,863	(20,129)	2,866	–	**219,600**	–	**219,600**
Grant of equity-settled share options to employees	–	2,747	–	–	**2,747**	–	**2,747**
Transfer of expired share option reserves to accumulated losses	–	(97,812)	–	97,812	–	–	–
Balance at 30 June 2026	**33,631,300**	**22,016**	–	**(17,449,094)**	**16,204,222**	**2,072,242**	**18,276,464**
Balance at 1 January 2025	33,669,437	(533,484)	(2,866)	(18,846,942)	**14,286,145**	2,636,070	**16,922,215**
Loss for the period, representing total comprehensive income for the period	–	–	–	(38,603)	**(38,603)**	(577,959)	**(616,562)**
Reduction of share capital pursuant to acquisition of business and certain assets	(275,000)	–	–	–	**(275,000)**	–	**(275,000)**
Grant of equity-settled share options to employees	–	9,983	–	–	**9,983**	–	**9,983**
Balance at 30 June 2025	**33,394,437**	**(523,501)**	**(2,866)**	**(18,885,545)**	**13,982,525**	**2,058,111**	**16,040,636**

Company	Share capital	Other reserves	Treasury shares	Accumulated losses	Total
	$	$	$	$	$
Balance at 1 January 2026	33,394,437	145,399	(2,866)	(19,603,762)	**13,933,208**
Loss for the period, representing total comprehensive income for the period	–	–	–	(110,907)	**(110,907)**
Exercise of share options and reissue of treasury shares	236,863	(20,129)	2,866	–	**219,600**
Grant of equity-settled share options to employees	–	2,747	–	–	**2,747**
Transfer of expired share option reserves to accumulated losses	–	(97,812)	–	97,812	–
Balance at 30 June 2026	**33,631,300**	**30,205**	–	**(19,616,857)**	**14,044,648**
Balance at 1 January 2025	33,669,437	127,249	(2,866)	(21,878,146)	**11,915,674**
Profit for the period, representing total comprehensive income for the period	–	–	–	162,305	**162,305**
Reduction of share capital pursuant to acquisition of business and certain assets	(275,000)	–	–	–	**(275,000)**
Grant of equity-settled share options to employees	–	9,983	–	–	**9,983**
Balance at 30 June 2025	**33,394,437**	**137,232**	**(2,866)**	**(21,715,841)**	**11,812,962**

D CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

	1H2026 (Unaudited) $	1H2025 (Unaudited) $
Cash flows from operating activities		
Loss before tax	**(40,181)**	**(616,562)**
Adjustments:		
Depreciation of plant and equipment	426,030	466,260
Depreciation of right-of-use assets	1,138,473	1,503,828
Doubtful debts recovered	-	(3,063)
Plant and equipment written off	14,627	8,320
Gain from disposal of plant and equipment	-	(70,000)
Finance costs	399,483	451,727
Interest income	(25,258)	(72,843)
Grant of equity-settled share options for employees	2,747	9,983
Share of results of associate	(214,343)	(170,634)
Operating cash flows before changes in working capital	**1,701,578**	**1,507,016**
Changes in working capital		
Decrease in inventories	54,986	41,224
Decrease/(Increase) in trade receivables, other receivables and deposits, and prepayments	(352,815)	(759,322)
(Decrease)/Increase in trade and other payables	59,239	193,714
Decrease in deferred income	(150,368)	(164,870)
Net cash flows from operating activities	**1,312,620**	**817,762**
Cash flows from investing activities		
Interest received	25,258	72,843
Addition in investments in other financial assets	(1,003,755)	(194,166)
Loan to related party	(1,300,000)	-
Proceeds from disposal of plant and equipment	-	70,000
Purchase of plant and equipment (Note N8.1)	(138,119)	(1,756,931)
Purchase of medical equipment under hire purchase (Note N8.2)	-	(474,060)
Net cash flows used in investing activities	**(2,416,616)**	**(2,282,314)**
Cash flows from financing activities		
Decrease in cash pledged as security	295,920	-
Interest paid	(390,042)	(437,324)
Proceeds from issuance of share capital	219,600	-
Payment of principal portion of borrowings	(1,260,724)	(1,173,761)
Net cash flows used in financing activities	**(1,135,246)**	**(1,611,085)**
Net decrease in cash and cash equivalents	(2,239,242)	(3,075,637)
Cash and cash equivalents at beginning of period	5,694,448	7,991,497
Cash and cash equivalents at end of period	**3,455,206**	**4,915,860**

E. NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

N1 Corporate information

AsiaMedic Limited (the "**Company**") is incorporated and domiciled in Singapore and whose shares are publicly traded on the Catalist of the Singapore Exchange Securities Trading Limited. These condensed interim consolidated financial statements as at and for the six months ended 30 June 2026 comprise the Company and its subsidiaries (collectively, the "**Group**").

The principal activities of the Company are those relating to investment holding and the provision of management services.

The principal activities of the Group are:
(a) Provision of diagnostic imaging and radiology services.
(b) Provision of medical wellness and health screening services.
(c) Provision of primary healthcare services.

Following the divestment of a 60% equity interest in AsiaMedic Astique the Aesthetic Clinic Pte. Ltd. ("**AATAC**") in November 2025, as previously disclosed in the Company's FY2025 Annual Report, the Group's remaining 40% interest in AATAC is equity accounted for as an associate. The Group's investment in associates as at 30 June 2026 comprises interests in Positron Tracers Pte. Ltd. ("**PTPL**") and AATAC.

N2 Basis of preparation

The condensed interim financial statements for the six months ended 30 June 2026 have been prepared in accordance with SFRS(I) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last annual financial statements for the year ended 31 December 2025.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s.

The condensed interim financial statements are presented in Singapore dollar which is the Company's functional currency.

The financial statements have been prepared on a going concern basis as the management is reasonably confident that the Group will be able to pay its debts as and when they fall due as the Group is expected to be able to generate sufficient operating cash flows and will have sufficient funds for its operations.

N2.1 New and amended standards adopted by the Group

No new or amendment to the Singapore Financial Reporting Standards (International) has become applicable to the Group for the current reporting period.

N2.2 Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2025.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are:

- Impairment of plant and equipment and right-of-use assets: key assumptions underlying recoverable amounts.
- Impairment of amounts owing by subsidiaries to the Company: key assumptions on the measurement of expected credit loss (ECL) allowance

N2.3 Impairment testing

Testing of non-financial assets of plant and equipment ("PE") and right-of-use assets ("ROUA")

The recoverable amounts of PE and ROUA are based on the value in use of the cash generating unit ("CGU"). Value in use was determined by discounting the future cash flows to be generated from the continuing use of the CGU. Value in use as at 30 June 2026 was determined similarly to the 31 December 2025 impairment test, and was based on the following key assumptions:

- Projections for an initial 5-year period based on past performance and adjusted for sales/market trends and the strategic decisions made in respect of the CGU. Projections beyond the 5-year period are extrapolated using a zero annual growth rate.
- Pre-tax discount rate of 7.33% pa.

Testing of amounts owing by subsidiaries to the Company

Following management's impairment assessment, no impairment loss was recognised for the financial period on amounts owing by subsidiaries to the Company.

N3 Segment and revenue information

For management purposes, the Group regards the rendering of medical wellness and health screening services, diagnostic imaging and radiology services and primary healthcare services as a single segment. Management has not identified any business or operating units separately for purpose of making decisions about resource allocation and performance assessment.

The Group's revenue is derived from operations located in Singapore.

N4 Disaggregation of revenue

	Group	
	1H2026	**1H2025**
	$	$
Major service lines:		
Diagnostic imaging and radiology services	13,019,894	10,647,916
Medical wellness and health screening services	2,613,298	4,509,151
Primary healthcare services	1,248,070	1,299,051
Medical aesthetic services	-	807,686
	16,881,262	17,263,804
Less: Elimination of intercompany transactions	(649,309)	(648,335)
	16,231,953	16,615,469
Timing of transfer of goods or services:		
At a point in time	16,231,953	16,615,469

N5 Loss before tax

N5.1 Significant items

	Group	
	1H2026	**1H2025**
	$	$
Income:		
Grant income	27,687	100,194
Sub-lease income	176,512	176,512
Interest income	25,258	72,843
Expenses:		
Interest on borrowings:		
Hire purchase loans	182,951	180,927
Term loan	2,230	7,652
Lease liabilities	204,861	248,745

N5.2 Related party transactions

In addition to the related party information disclosed elsewhere in the financial statements, the following significant transactions between the Group and related parties took place at terms agreed between the parties during the financial period:

	Group	
	1H2026	**1H2025**
	$	$
Purchase of consumables from associate	257,640	210,900
Loan from a subsidiary to its shareholder	1,300,000	-

In 1H2026, Asiamedic Sunway Pte. Ltd. (a subsidiary of the Group) extended interest-free loans of $1.3 million to each of its two 50% shareholders. Such loans are unsecured and repayable on demand. The loan extended to AsiaMedic Limited is eliminated on consolidation, while the loan extended to Sunway Equity Holdings Pte. Ltd. is reflected in the Group's financial statements.

N6 Income tax expense

There is no income tax expense for the six months ended 30 June 2026 as the Group incurred a loss for the period.

N7 Loss per share

Basic loss per share amounts are calculated by dividing loss for the period, net of tax, attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the financial period.

There were no potential dilutive ordinary shares. Share options are not included in the calculation of the diluted loss per share because they are anti-dilutive.

The following table reflects the share data used in the computation of loss per share:

	Group	
	1H2026	**1H2025**
	Number of shares	Number of shares
Weighted average number of ordinary shares for basic and diluted loss per share computation	1,137,059,839	1,129,522,270

N8 Plant and equipment and right-of-use assets

N8.1 Purchase of plant and equipment ("PE")

	Group 1H2026 $	Group 1H2025 $
Aggregate cost of PE acquired, excluding reinstatement assets	38,886	1,168,947
Add: Payables for PE at 1 January	390,450	923,408
Less: Payables for PE at 30 June	(291,217)	(335,424)
Net cash outflow for purchase of PE presented in consolidated statement of cash flows	138,119	1,756,931

N8.2 Right-of-use assets

Group	Premises $	Medical Equipment $	Total $
Cost:			
As at 1 January 2025	19,354,925	11,581,805	30,936,730
Modifications	(122,555)	(180,000)	(302,555)
Derecognition of previously-owned subsidiary	(1,120,253)	-	(1,120,253)
As at 31 December 2025, 1 January 2026 and 30 June 2026	18,112,117	11,401,805	29,513,922
Accumulated depreciation and impairment loss:			
As at 1 January 2025	8,440,286	359,000	8,799,286
Depreciation charge	1,727,357	762,023	2,489,380
Derecognition of previously-owned subsidiary	(482,329)	-	(482,329)
As at 31 December 2025 and 1 January 2026	9,685,314	1,121,023	10,806,337
Depreciation charge	757,461	381,012	1,138,473
As at 30 June 2026	10,442,775	1,502,035	11,944,810
Net book value:			
As at 31 December 2025	8,426,803	10,280,782	18,707,585
As at 30 June 2026	7,669,342	9,899,770	17,569,112

Company	Premises $	Total $
Cost:		
As at 31 December 2025, 1 January 2026 and 30 June 2026	12,590,013	12,590,013
Accumulated depreciation and impairment loss:		
As at 1 January 2025	7,831,314	7,831,314
Depreciation charge	1,013,028	1,013,028
As at 31 December 2025 and 1 January 2026	8,844,342	8,844,342
Depreciation charge	482,100	482,100
As at 30 June 2026	9,326,442	9,326,442
Net book value:		
As at 31 December 2025	3,745,671	3,745,671
As at 30 June 2026	3,263,571	3,263,571

N8.2 Right-of-use assets (cont'd)

Non-cash transaction

	Group	
	1H2026	**1H2025**
	$	$
Payables for medical equipment at 1 January	-	474,060
Payable for medical equipment at 30 June	-	-
Net cash outflow for purchase of medical equipment presented in consolidated statement of cash flows	-	474,060

N9 Borrowings

	Group		Company	
	30.6.2026	**31.12.2025**	**30.06.2026**	**31.12.2025**
	$	$	$	$
Current				
Hire-purchase loans (please see note (a) below)	820,788	807,672	–	–
Term loan (please see note (b) below)	85,000	187,000	–	–
Lease liabilities (unsecured)	1,227,503	1,455,805	761,681	989,983
	2,133,291	2,450,477	761,681	989,983
Non-current				
Hire-purchase loans (please see note (a) below)	7,098,190	7,502,333	–	–
Lease liabilities (unsecured)	7,374,009	7,913,404	3,068,024	3,376,470
	14,472,199	15,415,737	3,068,024	3,376,470
Total	**16,605,490**	**17,866,214**	**3,829,705**	**4,366,453**

Group	**As at 01.01.2026 $**	**Principal and interest payments $**	**Interest expense $**	**As at 30.06.2026 $**
Hire-purchase loans (please see note (a) below)	8,310,005	(573,978)	182,951	7,918,978
Term loan (please see note (b) below)	187,000	(104,230)	2,230	85,000
Lease liabilities (unsecured)	9,369,209	(972,558)	204,861	8,601,512
	17,866,214	**(1,650,766)**	**390,042**	**16,605,490**

Details of any collateral:

(a) The hire-purchase loans are secured by medical equipment with carrying amount of $9,899,769 (31 December 2025: $10,280,782) and corporate guarantees from the Company.

(b) The term loan is secured by a corporate guarantee from the Company.

N10 Share capital

	Group and Company	
	No. of ordinary shares	$
As at 1 January 2026	1,129,522,270	33,394,437
Movement during the period	18,300,000	236,863
As at 30 June 2026	1,147,822,270	33,631,300

As at 30 June 2026, the number of ordinary shares in issue was 1,147,822,270 (31 December 2025: 1,129,522,270 ordinary shares, excluding 100,000 treasury shares). See Section F, paragraph 1(d)(ii) below.

The Company's subsidiaries do not hold any shares in the Company as at 30 June 2026 and 31 December 2025.

N11 Treasury shares

	Group and Company	
	No. of ordinary shares	$
As at 1 January 2026	100,000	2,866
Movement during the period	(100,000)	(2,866)
As at 30 June 2026	-	-

N12 Earnings before interest, tax, depreciation and amortisation ("EBITDA")

	1H2026	**1H2025**
Loss for the period	(40,181)	(616,562)
Add:		
Depreciation of non-current assets:		
- Plant and equipment	426,030	466,260
- Right-of-use-assets	1,138,473	1,503,828
Finance costs	399,483	451,727
Interest Income	(25,258)	(72,843)
Income tax expense	–	–
EBITDA	**1,898,547**	**1,732,410**

EBITDA for 1H2026 was S$1,898,547 (1H2025: S$1,732,410, restated), following a refinement to the Group's EBITDA calculation to exclude interest income. Accordingly, the comparative figures for 1H2025 have been restated on the same basis to enhance consistency and comparability. This change relates solely to the presentation of the EBITDA supplementary measure and does not affect the Group's reported financial results.

N13 Commitment

Please refer to Section F, paragraph 16.

F INFORMATION REQUIRED UNDER APPENDIX 7C OF THE CATALIST RULES

The following disclosures are in accordance with Appendix 7C Financial Statements and Dividend Announcement of the Listing Manual Section B: Rules of Catalist (the "Catalist Rules") of the Singapore Exchange Securities Trading Limited (the "SGX-ST") and do not form part of the condensed interim financial statements set out on pages 1 to 10 of this announcement.

1. (a)(i) An income statement and statement of comprehensive income, or a statement of comprehensive income, for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year.

Please refer to Section A.

(a)(ii) Significant items

Please refer to Note N5.1.

(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

Please refer to Section B.

(b)(ii) Aggregate amount of group's borrowings and debt securities.

Please refer to Note N9.

(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

Please refer to Section D.

(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

Please refer to Section C.

(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

As at 30 June 2026, the number of ordinary shares in issue was 1,147,822,270 (31 December 2025: 1,129,522,270 ordinary shares, excluding 100,000 treasury shares). The issued share capital as at 30 June 2026 was $33,631,300 (31 December 2025: $33,394,437).

The change in issued share capital and number of ordinary shares in issue was attributable to the exercise of 18,300,000 options granted under AsiaMedic Employee Share Option Scheme 2016 at an exercise price of $0.012 each.

During the period, the 100,000 treasury shares had been used in conjunction with the exercise of the 18,300,000 options (treasury shares as at 30 June 2026: Nil; 30 June 2025: 100,000).

As at 30 June 2026, there were outstanding options for conversion into 31,700,000 (30 June 2025: 50,819,677) ordinary shares.

(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

As at 30 June 2026, the number of ordinary shares in issue was 1,147,822,270 (nil treasury shares) (31 December 2025: 1,129,522,270 ordinary shares, excluding 100,000 treasury shares).

(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

	As at 1 January 2026	Share buyback	Sales	Transfers	Disposal	Cancellation or use	As at 30 June 2026
Number of treasury shares	100,000	–	–	–	–	(100,000)	-

(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.

Not applicable. The Company does not have subsidiary holdings during and as at the end of the current financial period report on.

2. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.

The figures have not been audited nor reviewed by the Company's auditor.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter).

Not applicable.

3A. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:
(a) Updates on the efforts taken to resolve each outstanding audit issue.
(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.
This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable. No adverse opinion, qualified opinion or disclaimer of opinion.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

Please refer to Note N2.

5. **If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.**

Please refer to Note N2.1.

6. **Earnings per ordinary share of the Group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.**

Please refer to consolidated statement of profit or loss and Note N7.

7. **Net asset value (for the issuer and Group) per ordinary share based on issued share capital excluding treasury shares of the issuer at the end of the:**
(a) current financial period reported on; and
(b) immediately preceding financial year

	Group		**Company**	
	30 June 2026	**31 December 2025**	**30 June 2026**	**31 December 2025**
	Cent	Cent	Cent	Cent
Net asset value per ordinary share	1.41	1.42	1.22	1.23

The total number of shares used for the computation of net asset value per share as at 30 June 2026 is 1,147,822,270 ordinary shares (31 December 2025: 1,129,522,270 ordinary shares excluding 100,000 treasury shares).

8. **A review of the performance of the Group, to the extent necessary for a reasonable understanding of the Group's business. It must include a discussion of the following:**
(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and
(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

The Group recorded revenue of $16.2 million for the six months ended 30 June 2026 ("**1H2026**"), compared to $16.6 million for the six months ended 30 June 2025 ("**1H2025**"), a decrease of $0.4 million (2%). The decrease was primarily attributable to the absence of revenue from the School Health Screening Projects in 1H2026 and the cessation of revenue from the Group's medical aesthetic business following the disposal of a controlling interest in 2025. These were partially offset by continued growth in the Group's diagnostic imaging and radiology services, which increased 22% to $13.0 million (1H2025: $10.6 million) and remained the Group's largest revenue contributor, accounting for over 80% of total group revenue. Medical wellness and health screening services declined 42% to $2.6 million (1H2025: $4.5 million), mainly due to the absence of the School Health Screening Projects, while primary healthcare services remained relatively stable at $1.2 million (1H2025: $1.3 million).

Other income decreased 24% to $0.3 million (1H2025: $0.4 million), mainly due to lower grant income and interest income.

Personnel expenses decreased 7% to $7.5 million (1H2025: $8.0 million). While manpower costs generally increased in the Group's diagnostic imaging business to support higher imaging activities, this was more than offset by lower personnel expenses following the completion of the School Health Screening Projects. Depreciation of plant and equipment and right-of-use assets decreased 9% and 24%, respectively, mainly due to the revision of the useful lives of certain plant and equipment and renovations adopted in December 2025, as disclosed in the Group's FY2025 financial statements. Maintenance of equipment increased 30% to $0.3 million (1H2025: $0.2 million), mainly due to higher maintenance costs following the expiry of warranties for certain medical equipment. Laboratory and consultancy fees increased 7% to $3.6 million, broadly in line with higher diagnostic imaging volumes.

Facility and administration fees increased 3% to $0.7 million, mainly due to increased collaboration arrangements with strategic business partners to support the Group's diagnostic imaging business. Finance costs decreased 12% to $0.4 million, reflecting the scheduled repayment of borrowings. Other operating expenses decreased 13% to $1.7 million (1H2025: $2.0 million), mainly due to the Group's continued cost management initiatives, resulting in lower advertising and marketing expenses and lower general repair and maintenance expenses.

The Group's share of results of associates increased 26% to $0.2 million (1H2025: $0.2 million), mainly due to improved performance of Positron Tracers Pte. Ltd. ("**PTPL**") together with the Group's share of results from AsiaMedic Astique the Aesthetic Clinic Pte. Ltd. ("**AATAC**") following the disposal of the controlling interest in November 2025. In the corresponding period last year, the share of results comprised PTPL only.

Overall, the Group’s loss before tax and net loss for the period narrowed significantly to approximately $40,000 in 1H2026 from $0.6 million in 1H2025. The improvement was mainly driven by the improved performance of the Novena imaging centre, together with lower depreciation arising from a reassessment of useful lives of certain plant and equipment and renovations, and lower finance costs and higher contributions from the Group’s associates.

Basic loss per share was 0.006 Singapore cents in 1H2026, compared to 0.003 Singapore cents in 1H2025.

Statements of Financial Position

Non-current assets

Non-current assets decreased by $1.3 million to $24.9 million as at 30 June 2026, from $26.2 million as at 31 December 2025, mainly due to depreciation of right-of-use assets and plant and equipment, partially offset by the increase in the carrying value of the Group's investment in associates arising from its share of profits.

Current assets

Current assets remained relatively stable at $17.0 million as at 30 June 2026 and 31 December 2025. Other receivables and deposits increased to $3.3 million (31 December 2025: $1.8 million), mainly due to a $1.3 million interest-free loan extended by Asiamedic Sunway Pte. Ltd. (”**ASPL**”) to Sunway Equity Holdings Pte. Ltd., during the period. The loan is unsecured and repayable on demand. Further details are set out in Note N5.2. Other financial assets relate to short-term Treasury bills and credit-linked notes which are rolled over on a monthly basis, which increased to $5.0 million (31 December 2025: $4.0 million) following additional investments during the period. These were partly offset by lower cash and cash equivalents of $3.5 million (31 December 2025: $5.7 million) and the release of cash previously pledged as security.

Current liabilities

Current liabilities decreased to $7.6 million from $8.1 million as at 31 December 2025, mainly due to lower other payables and accruals, contract liabilities and current borrowings, partially offset by higher trade payables.

Net current assets increased to $9.5 million from $8.9 million as at 31 December 2025.

Non-current liabilities

Non-current liabilities decreased to $16.1 million from $17.0 million as at 31 December 2025, mainly due to the scheduled repayment of long-term borrowings. Provision for reinstatement and deferred tax liabilities remained substantially unchanged.

Statements of Cash Flows

Net cash generated from operating activities improved to $1.3 million in 1H2026 from $0.8 million in 1H2025, mainly due to improved operating performance and favourable working capital movements during the period.

Net cash used in investing activities amounted to $2.4 million in 1H2026, compared to $2.3 million in 1H2025, mainly due to the loan extended to a related party during the period and additional investments in other financial assets, partially offset by lower capital expenditure on plant and equipment.

Net cash used in financing activities decreased to $1.1 million in 1H2026 from $1.6 million in 1H2025, mainly due to lower repayments of borrowings, proceeds from the exercise of share options and the release of cash pledged as security.

As a result of the above, the Group recorded a net decrease in cash and cash equivalents of $2.2 million in 1H2026, compared to a decrease of $3.1 million in 1H2025. Cash and cash equivalents stood at $3.5 million as at 30 June 2026, compared to $5.7 million as at 31 December 2025.

In addition to cash and cash equivalents, the Group held other financial assets of $5.0 million as at 30 June 2026 (31 December 2025: $4.0 million), comprising short-term Treasury bills and credit-linked notes which are rolled over on a monthly basis. Taking these into account, the Group's total cash and liquid financial assets stood at $8.5 million as at 30 June 2026 (31 December 2025: $9.7 million).

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

No forecast or prospect statement has been previously disclosed to shareholders.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months.

Singapore's healthcare sector continues to benefit from long-term structural trends, including an ageing population and growing demand for diagnostic imaging and preventive healthcare services. At the same time, the operating environment remains competitive, with continuing manpower cost pressures and rising operating costs across the healthcare industry.

Diagnostic imaging remains the Group's core business and principal revenue contributor. The Group will continue to focus on strengthening its diagnostic imaging capabilities while improving utilisation across its existing facilities. The Group also remains committed to growing its medical wellness and health screening business through its corporate and institutional partnerships.

Looking ahead, the Group will continue to focus on operational efficiency, prudent cost management and disciplined capital allocation while exploring selective growth opportunities that complement its existing healthcare platform. The Board remains cautiously optimistic that the Group is well positioned to benefit from the long-term demand for quality diagnostic imaging and preventive healthcare services.

11. Dividend information.

a) Whether an interim (final) ordinary dividend has been declared (recommended).

Nil

b) (1) Amount per share: Nil cents

(2) Previous corresponding period: Nil cents

c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).

N/A

d) **The date the dividend is payable:** N/A

e) **The date on which Registrable Transfers received by the company (up to 5.00 pm) will be registered before entitlements to the dividend are determined.**

N/A

12. If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision.

No dividend has been declared as the Group registered a loss for the period.

13. If the group has obtained general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920 (1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

No IPT mandate has been obtained.

14. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720.

The Company has received undertaking from all its Directors and executive officers in the format as set out in Appendix 7H under Rule 720(1) of the Catalist Rules of the SGX-ST.

15. Disclosure of acquisition (including incorporations) and sale of shares under Catalist Rule 706A.

There was no acquisition (including incorporation) and/or sale of shares by the Company in 1H2026 which requires disclosure pursuant to Rule 706A of the Catalist Rules.

16. Confirmation pursuant to Rule 705(5).

On behalf of the Board of Directors of the Company, we, the undersigned, hereby confirm to the best of our knowledge that nothing has come to the attention of the Board of Directors of the Company which may render the financial statements for the six-month period ended 30 June 2026 to be false or misleading in any material aspect.

On behalf of the Board of Directors

Charles Wang Chong Guang　　　　Alice Ng Bee Yee

BY ORDER OF THE BOARD

Foo Soon Soo (Ms)
Company Secretary

Singapore
14 August 2026

This announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954.